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Abstract
Aims Hyperkalaemia risk precludes optimal renin–angiotensin–aldosterone system inhibitor use in patients with heart fail-
ure (HF), particularly those with chronic kidney disease (CKD). Patiromer is a sodium-free, non-absorbed potassium (K+)-
binding polymer approved for the treatment of hyperkalaemia. In PEARL-HF, patiromer 25.2 g (fixed dose) prevented
hyperkalaemia in HF patients with or without CKD initiating spironolactone. The current study evaluated the effectiveness
of a lower starting dose of patiromer (16.4 g/day) followed by individualized titration in preventing hyperkalaemia and
hypokalaemia when initiating spironolactone.
Methods and results This open-label 8-week study enrolled 63 patients with CKD, serum K+ 4.3–5.1 mEq/L, and chronic HF,
who, based on investigator opinion, should receive spironolactone. Eligible patients started spironolactone 25 mg/day and
patiromer 16.8 g/day (divided into two doses), with patiromer titrated to maintain serum K+ 4.0–5.1 mEq/L. Mean (standard
deviation) serum K+ was 4.78 (0.51) mEq/L at baseline; weekly values were 4.48–4.70 mEq/L during treatment. Serum K+ of
3.5–5.5 mEq/L at the end of study treatment (primary endpoint) was achieved by 57 (90.5%) patients; 53 (84.1%) had serum
K+ 4.0–5.1 mEq/L. One patient (1.6%) developed hypokalaemia, and two patients (3.2%) developed hypomagnesaemia.
Spironolactone was increased to 50 mg/day in all patients; 43 (68%) patients required one or more patiromer dose titration.
Adverse events (AEs) occurred in 36 (57.1%) patients, with a low rate of discontinuations [four (6.3%) patients]. The most com-
mon AE was mild to moderate abdominal discomfort [four (6.3%) patients].
Conclusions In this open-label study, patiromer 16.8 g/day followed by individualized titration maintained serum K+ within
the target range in the majority of patients with HF and CKD, all of whom were uptitrated to spironolactone 50 mg/day,
patiromer was well tolerated, with a low incidence of hyperkalaemia, hypokalaemia, and hypomagnesaemia.
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Introduction
Renin–angiotensin–aldosterone system inhibitors (RAASi) are
guideline recommended with a Class 1 indication to reduce
cardiovascular and total mortality in patients with heart fail-
ure (HF) and reduced left ventricular ejection fraction
(EF).1–6 In patients with HF with reduced EF (HFrEF) at highest
risk of cardiovascular death, such as those with diabetes
mellitus and/or chronic kidney disease (CKD), the risk of
worsening renal function and hyperkalaemia often precludes
or limits the use of optimal doses of RAASi, especially miner-
alocorticoid receptor antagonists (MRAs).7–9 Given that the
risk of hyperkalaemia may change over time in patients with
HF due to dose changes in RAASi, dietary changes, use of di-
uretics, and changes in renal function, it is desirable to have a
titratable drug that can be used to manage serum potassium
(K+) without resorting to discontinuation or dose reduction of
evidence-based HF and CKD treatments.
Patiromer is a non-absorbed K+-binding polymer that uses
calcium rather than sodium as the cation for exchange with
K+. It is approved for the treatment of hyperkalaemia in the
USA and in Europe.10–12 Patiromer has been shown to reduce
serum K+ in hyperkalaemic patients with CKD with or without
other co-morbidities, such as HF, diabetes mellitus, and/or
hypertension.13–15 Patiromer has also been demonstrated in
a randomized, double-blind, placebo-controlled study to
prevent hyperkalaemia in normokalaemic patients with HF
with or without CKD who were initiated on spironolactone.16
This study used a relatively high fixed total daily dose of
patiromer (25.2 g given as a divided dose twice daily), which
was associated with approximately 7% incidence of
hypokalaemia (serum K+ <3.5 mEq/L).16 The present study
was designed to assess a lower starting dose of patiromer
followed by individualized titration based on serum K+ levels
in preventing hyperkalaemia and hypokalaemia in patients
with HF and CKD who were initiated on spironolactone
25 mg/day in addition to standard therapy, including one or
more of the following: an angiotensin-converting enzyme in-
hibitor (ACEi) and angiotensin receptor blocker (ARB) or a
beta adrenergic receptor blocker (BB).
It was hypothesized that the lower starting dose followed
by individually optimized dose titration would minimize the
risk of hypokalaemia and still prevent hyperkalaemia, thus
allowing continued usage of RAASi in these patients. The sec-
ondary aim of the study was to assess the effects of
patiromer on serum K+ and the safety and tolerability of
patiromer in HF patients with CKD.
Methods
This 8 week, open-label study (registered at ClinicalTrials.gov,
NCT01130597) was conducted at 13 centres in Georgia and
Slovenia between May 2010 and September 2010. All partic-
ipating sites received approval from their nationally or locally
appointed Independent Ethics Committee, and all patients
provided written informed consent. The study was performed
in accordance with the Declaration of Helsinki, current local
and national regulations, the International Conference on
Harmonization, and Good Clinical Practice guidelines and ful-
filled other applicable requirements governing the conduct of
human clinical trials.
Patients and assessments
Eligible patients were ≥18 years old with chronic HF who, in
the opinion of the investigator, should receive spironolactone
therapy. Patients also had to have CKD with a screening esti-
mated glomerular filtration rate (eGFR) of <60 mL/min/
1.73 m2 based on central laboratory creatinine measurement
and calculated using the Modification of Diet in Renal Disease
formula.17 Serum K+ at screening and at baseline had to be
4.3–5.1 mEq/L, and patients had to be receiving at least
one of the following: ACEi, ARB, or a BB. Patients were ex-
cluded if they had a history of severe gastrointestinal (GI) dis-
orders, major GI surgery, bowel obstruction, or swallowing
disorders, or if they had severe or unstable hypertensive or
cardiovascular disease or severe renal disease, including his-
tory of or anticipated need for heart or kidney transplanta-
tion or dialysis during the study. Prohibited medications
during the study included polymer-based drugs, other K+
binders or phosphate binders, other K+-sparing diuretics (in-
cluding non-study aldosterone antagonists), and K+ supple-
ments. Investigators were instructed to maintain a constant
dose of cardiac medications during the entire study. Oral di-
uretics (loop and thiazide) were permitted during the study
if the dose was stable for at least 21 days prior to the start
of the study and was expected to remain stable during the
study.
Patients who completed screening and satisfied the eligi-
bility criteria returned to the clinic for baseline assessments,
which included a physical examination, weight and height,
resting heart rate, supine blood pressure, a 12-lead electro-
cardiogram (ECG), determination of serum K+, and clinical
laboratory tests, including serum chemistry, haematology,
and urinalysis. Patients who continued to satisfy all eligibility
criteria were enrolled in the study and were initiated on
spironolactone 25 mg once daily and patiromer 16.8 g/day
on Day 1. Patiromer was supplied as a powder for oral sus-
pension, which was to be mixed with water or a low-K+ food
and consumed with meals—8.4 g with breakfast and 8.4 g
with dinner.
The patiromer and spironolactone dosing algorithm is
shown in Table S1 of the Supporting Information. Starting
on Day 3, the patiromer dose could be adjusted up or down
in increments of 8.4 g/day based on the patient’s local
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laboratory serum K+ value in order to maintain serum K+
within the target range of 4.0–5.1 mEq/L. The only exception
was if the serum K+ was <4.0 mEq/L on a visit when the pa-
tient was eligible for a spironolactone dose increase. In such
cases, the patiromer dose was to be maintained. Patiromer
doses could be titrated to a minimum of 0 g/day or to a max-
imum of 50.4 g/day. Starting on Day 7, the spironolactone
dose was increased to 50 mg once daily provided that the
patient’s serum K+ concentration was ≤5.1 mEq/L;
spironolactone dose reductions were not allowed. During
the course of the study, the minimum spironolactone dose
was 25 mg/day, and the maximum was 50 mg/day. Patiromer
and spironolactone dose adjustments were not permitted on
the same day. Patients were to discontinue both patiromer
and spironolactone and were to be withdrawn from the study
if their local laboratory serum K+ was <3.5 or >5.5 mEq/L at
two consecutive visits despite titration of patiromer or
spironolactone on the first of the two visits.
During the 8 week treatment period, serum K+ was moni-
tored at each clinic visit, scheduled on Day 3 and weekly from
Weeks 1 through 8. At each visit, 12-lead ECG was obtained,
the need for patiromer dose titration was assessed (except at
the Week 8 visit), and concomitant medications and adverse
events (AEs) were assessed. Vital signs, body weight, and an
evaluation for spironolactone uptitration were assessed
weekly from Weeks 1 through 8 (except spironolactone
uptitration assessment at the Week 8 visit). Serum chemistry
testing was performed at Weeks 2, 4, 6, and 8, and
haematology testing was performed at Weeks 4 and 8. One
week after completion of the treatment period (or following
premature discontinuation of patiromer and spironolactone),
patients returned to the clinic for a safety follow-up visit.
Clinical endpoints
The primary efficacy outcome was the proportion of patients
with a serum K+ 3.5–5.5 mEq/L at the end of study treatment
(i.e., the final visit of the treatment period while on study
drug). Secondary endpoints included (1) proportion of pa-
tients with serum K+ 3.5–5.5 mEq/L, by visit and during the
entire treatment period; (2) proportion of patients with se-
rum K+ 4.0–5.1 mEq/L, by visit and during the entire treat-
ment period; (3) proportion of patients whose
spironolactone dose could be increased to 50 mg/day; (4)
mean number of patiromer titrations; (5) proportion of pa-
tients requiring patiromer uptitration or downtitration; (6)
mean time to the first patiromer titration; and (7) mean dose
of patiromer by visit and at the end of the study.
The safety of patiromer was assessed based on (1) AEs re-
corded during the study and through 7 days after the last
dose of study drug; (2) clinically significant changes from
baseline in clinical laboratory (haematology and serum chem-
istry) values, vital signs, and ECG parameters and proportion
of patients who discontinued the study owing to
hyperkalaemia (serum K+ >5.5 mEq/L); and (3) proportion
of patients discontinuing because of hypokalaemia (serum
K+ <3.5 mEq/L on two consecutive visits despite patiromer
or spironolactone dose titration on the first of the two visits).
Statistical analysis
A total of 63 patients were enrolled to ensure that at least 50
patients would receive patiromer and provide efficacy data
for analysis. The sample size was based on the patiromer
response predicted from the PEARL-HF study.16 For the primary
efficacy endpoint, the proportion of patients with serum K+
3.5–5.5 mEq/L at the end of the study treatment was summa-
rized along with 95% confidence intervals (CIs). The analysis pop-
ulation for the primary and secondary efficacy endpoints, and for
assessment of safety, was the intent-to-treat population (i.e., all
enrolled patients). Baseline values were obtained from the last
available measurement prior to the start of patiromer. For
categorical secondary endpoints, the proportion of patients and
95% CIs were summarized. AEs were summarized descriptively.
Statistical analyses were performed using SAS Version 9.4
(SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics and disposition
A total of 63 patients [100% White, 39 (61.9%) men] were en-
rolled in the study, all of whom received at least one dose of
patiromer and had at least one post-baseline serum K+ as-
sessment. The mean [standard deviation (SD)] age was 70.8
(8.5) years (Table 1). All patients had a history of HF with a
mean (SD) duration of 3.9 (4.1) years, which was character-
ized at study entry as New York Heart Association Class II
(46% of patients) or Class III (54%). Patients had a mean
(SD) EF of 38.6% (9.3%); 33 (52.4%) patients had an EF
<40% (Table 1). The aetiology of HF was ischaemic in 40
(63.5%) patients. Overall, 93.7% of patients had a history of
hypertension, and 42.9% had diabetes. All patients had
CKD; the mean (SD) eGFR was 46.2 (15.2) mL/min/1.73 m2
at baseline; 57 patients were in Stage 3a or 3b and six pa-
tients in Stage 4 or 5. The mean (SD) duration of CKD was
2.5 (3.3) years, and the most common aetiologies of CKD
were hypertension only (30.2%), hypertension and diabetes
(27.0%), and unknown (30.2%).
At baseline, all patients were receiving a RAASi or a BB; 45
(71.4%) patients were on an ACEi, 18 (28.6%) were on an
ARB, and 48 (76.2%) were on a BB (Table 1). One (1.6%) pa-
tient was on dual therapy of ACEi and ARB, 35 (55.6%) were
on dual therapy of ACEi and BB, 12 (19.0%) were on dual
therapy of ARB and BB, and no patient was on triple therapy
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(ACEi, ARB, and BB) (Table 1). Thirty-two (51%) patients were
receiving 50% or more of the maximal daily dose of an ACEi
or ARB, while 26 (41%) patients were receiving 25% or less
of the maximal daily dose of an ACEi or ARB. Of the 48
patients taking beta-blockers at baseline, 11 (23%) were re-
ceiving 50% or more of the maximal daily dose, while 13
(27%) were receiving 25% or less of the maximal daily dose.
In addition, 52 (82.5%) patients were on a diuretic at base-
line, and the same proportion (82.5%) was receiving diuretic
therapy during the study.
Fifty-six (88.9%) patients completed the 8 week treatment
period, and seven (11.1%) prematurely discontinued treat-
ment; the most common reason for discontinuation was AEs
(four patients; 6.3%) (see Supporting Information, Figure S1).
Efficacy
At baseline, the mean (SD) serum K+ was 4.78 (0.51) mEq/L.
Mean (SD) change in serum K+ from baseline to end of study
treatment was 0.13 (0.69) mEq/L, range: 1.9 to 1.3 mEq/L.
During the treatment period, weekly mean serum K+ values
were 4.48–4.70 mEq/L. At the end of study treatment, 57
(90.5%; 95% CI: 80.4%, 96.4%) patients had serum K+
3.5–5.5 mEq/L (primary endpoint), including five of six
patients with eGFR <30 mL/min/1.73 m2 at baseline. Fifty-
three (84.1%; 95% CI: 72.7%, 92.1%) patients had serum K+
4.0–5.1 mEq/L. Figure 1 shows the proportions of patients
with serum K+ in the ranges of 3.5–5.5 and 4.0–5.1 mEq/L at
all post-baseline visits. The proportion ranged from 91.2% to
100% for patients with serum K+ 3.5–5.5 mEq/L and from
72.6% to 90.3% for patients with serum K+ 4.0–5.1 mEq/L
(Figure 1). Serum K+ was maintained in the range of
3.5–5.5 mEq/L in 48 (76.2%; 95% CI: 63.8%, 86.0%) patients
and in the range of 4.0–5.1 mEq/L in 19 (30.2%; 95%
CI: 19.2%, 43.0%) patients during the entire treatment period.
The mean (SD) number of prescribed patiromer dose titra-
tions during the study was 1.3 (1.1): 20 (31.7%) patients did
not require any titration, 21 (33.3%) had one or more
uptitrations, 8 (12.7%) had one or more downtitrations, and
14 (22.2%) had both one or more uptitrations and one or
Table 1 Baseline demographic and clinical characteristics
Parameter Patiromer (N = 63)
Demographics
Age (years), mean ± SD 70.8 ± 8.5
Male, n (%) 39 (61.9)
White, n (%) 63 (100)
BMI (kg/m2), mean ± SD 28.6 ± 3.8
Cardiac history and parameters
HF duration (years), mean ± SD 3.9 ± 4.1
HF aetiology: ischaemic, n (%) 40 (63.5)
LVEF (%), mean ± SDa 38.6 ± 9.3
Patients with LVEF of <40%, n (%) 33 (52.4)
Patients with LVEF of 40–50%, n (%) 24 (38.1)
Patients with LVEF of >50%, n (%) 5 (7.9)
NYHA Class, n (%) II 29 (46.0)
III 34 (54.0)
CKD history
CKD duration (years), mean ± SDa 2.5 ± 3.3
CKD aetiology, n (%)a
Hypertension (only) 19 (30.2)
Hypertension and diabetes 17 (27.0)
Diabetes (only) 4 (6.3)
Urologic or congenital 2 (3.2)
Unknown 19 (30.2)
eGFR (mL/min/1.73 m2), mean ± SD 46.2 ± 15.2
Patients with eGFR (mL/min/1.73m2), n (%)
<15 1 (1.6)
15–<30 5 (7.9)
30–45 26 (41.3)
>45 31 (49.2)
ACR (mg/g), mean ± SD [n (%)]
<30 mg/g 10.8 ± 5.7 [28 (44.4)]
≥30 mg/g 749.6 ± 1341.9 [35
(55.6)]
Vital signs
Heart rate (b.p.m.) 70.5 ± 12.8
Systolic blood pressure (mmHg) 133.3 ± 16.6
Diastolic blood pressure (mmHg) 82.1 ± 7.6
Other co-morbid conditions
History of diabetes, n (%) 27 (42.9)
History of hypertension, n (%) 59 (93.7)
HF medications at baseline 63 (100)
Diuretics 52 (82.5)
Loop 46 (73.0)
Thiazide 11 (17.5)
ACEi 45 (71.4)
ARB 18 (28.6)
Beta-blocker 48 (76.2)
ACEi only 9 (14.3)
ARB only 5 (7.9)
Beta-blocker only 1 (1.6)
ACEi + ARB 1 (1.6)
ACEi + beta-blocker 35 (55.6)
ARB + beta-blocker 12 (19.0)
ACEi + ARB + beta-blocker 0
ACEi, angiotensin-converting enzyme inhibitor; ACR, albumin-to-
creatinine ratio; ARB, angiotensin receptor blocker; BMI, body mass
index; b.p.m., beats per minute; CKD, chronic kidney disease; eGFR,
estimated glomerular filtration rate; HF, heart failure; LVEF, left
ventricular ejection fraction; NYHA, New York Heart Association
functional class; SD, standard deviation.
an = 62.
Figure 1 Proportion of patients with serum K+ in the range of
3.5–5.5 mEq/L and 4.0–5.1 mEq/L by study visit. ET, end of treatment;
K+, potassium.
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more downtitrations. The median (95% CI) time to the first
patiromer dose titration was 21.0 (14.0, 36.0) days.
Over the course of the study, the mean (SD) duration of ex-
posure to patiromer was 53.9 (8.6) days, and the mean (SD)
dose was 18.7 (6.4) g/day. The mean (SD) dose of patiromer
at the end of the study was 19.6 (10.4) g/day. In the majority
of patients, the last prescribed dose was either 16.8 g/day
(44.4%) or 25.2 g/day (17.5%) (see Supporting Information,
Table S2). On average, serum K+ decreased by 0.34 mEq/L
1 week following an 8.4 g/day uptitration in patiromer dose
and increased by 0.46 mEq/L 1 week following an 8.4 g/day
downtitration of patiromer dose (Figure 2).
The mean (SD) duration of exposure to spironolactone was
53.6 (8.7) days. One patient initiated treatment with
spironolactone 50 mg/day (protocol deviation) and continued
this dose through the completion of the study. Of the 62 pa-
tients who initiated spironolactone treatment at 25 mg/day,
the MRA was successfully uptitrated to 50 mg/day in all 62
patients by Day 14 of the study. The uptitration occurred in
57 patients during the first week and in five during the sec-
ond week. The median time to titration was 8 days (range:
6–16 days). The mean (SD) dose of spironolactone during
the study treatment period was 45.5 (3.4) mg/day.
Patients’ dosing compliance with patiromer and
spironolactone was measured by examination of the drug sa-
chets and blister packs, respectively, which were returned to
the clinic at each visit. The mean (SD) dosing compliance rate
was 98.7% (1.9%) for patiromer and 98.5% (5.6%) for
spironolactone.
Safety
A total of 36 (57.1%) patients had at least one AE, regardless
of severity, seriousness, or relatedness to patiromer (Table 2);
the most common AEs (occurring in at least three patients)
were worsening of renal function in eight (12.7%) patients,
abdominal discomfort in four (6.3%) patients, and flatulence,
headache, and hypertension, each occurring in three (4.8%)
patients. In the majority of patients, the AEs were mild or
moderate in intensity (83.3%) and in most patients (69.5%)
were unrelated to patiromer. Mild peripheral oedema was re-
ported in two (3.2%) patients; both cases were considered
not related to patiromer by the investigator. In all eight pa-
tients with worsening of renal function, the AE was consid-
ered unrelated to patiromer by the investigator, and in
three patients, the AE was considered related to
spironolactone (see Supporting Information, Table S3). Eleven
patients had patiromer-related AEs, most commonly GI-
related (abdominal discomfort, three; flatulence, three;
diarrhoea, two; abdominal pain, one). All GI-related AEs were
reported as either mild or moderate. Four (6.3%) patients
had a total of six AEs that led to discontinuation of patiromer;
in three patients, the AEs leading to discontinuation were
serious (discussed below). The non-serious AE leading to
discontinuation was moderate diarrhoea.
During the treatment period through follow-up, six (9.5%)
patients had a total of nine serious AEs (SAEs); three patients
had a single, non-fatal SAE: acute renal failure in two patients
(see Supporting Information, Table S3) and subcutaneous ab-
scess in one patient. Three patients, all diabetic, experienced
fatal SAEs. One patient died because of sudden cardiac death
on Day 29 of the study. This patient’s last measured (on Day
28) serum K+ was 4.6 mEq/L and serum magnesium was
1.7 mg/dL. Two patients died after stopping patiromer: one
sudden death 5 days after completing study treatment and
one sudden cardiac death 26 days after prematurely
discontinuing patiromer treatment due to non-fatal SAEs,
including acute renal failure (see Supporting Information,
Table S3). The narratives for the three patients with fatal
SAEs are provided in Table S4 of the Supporting Information.
None of the SAEs, including the fatal events, were considered
by the study investigators as related to patiromer, and the
Figure 2 Serum K+ before and after an uptitration or downtitration.
*Total number of titrations during the study. K+, potassium; SD, standard
deviation.
Table 2 Safety summary
Parameter, n (%) (N = 63)
Any adverse event 36 (57.1)
Adverse eventsa occurring in ≥3 (~5%) patients
Worsening of renal functiona 8 (12.7)
Abdominal discomfort 4 (6.3)
Flatulence 3 (4.8)
Headache 3 (4.8)
Hypertension 3 (4.8)
Serious adverse events 6 (9.5)
Patiromer-related serious adverse events 0 (0)
Adverse event leading to study discontinuation 4 (6.3)
aAdverse events were coded to the preferred terms listed above
using the Medical Dictionary for Regulatory Activities Version
12.0, except for worsening of renal function, which includes the
preferred terms of renal failure acute (three patients), renal impair-
ment (three patients), and renal failure (two patients).
Patiromer: controlling serum K+ in patients with HF and CKD 261
ESC Heart Failure 2018; 5: 257–266
DOI: 10.1002/ehf2.12265
SAEs of acute renal failure for two patients were considered
to be related to spironolactone. Two of the three deaths
were considered by the Safety Review Board as unlikely to
be due to hypokalaemia or hyperkalaemia, and the relation-
ship to hypokalaemia or hyperkalaemia for the one death
that occurred 26 days after prematurely discontinuing
patiromer treatment could not be determined.
One (1.6%) patient developed hypokalaemia (3.1 mEq/L at
the Week 3 visit) based on prespecified criteria (serum K+
<3.5 mEq/L); patiromer was downtitrated, while the
spironolactone dose was maintained, and at the next visit
8 days later, the serum K+ was 3.9 mEq/L. No patient
discontinued the study because of hypokalaemia. A total of
15 (24%) patients developed hyperkalaemia (serum K+
>5.5 mEq/L): nine (14%) patients had an isolated event be-
fore or at the end of treatment; six (10%) patients had more
than one serum K+ value >5.5 mEq/L. Serum K+ was normal-
ized with individualized dose titration of patiromer in all but
one of these patients, with the exception being the patient
who was prematurely withdrawn from the study owing to
hyperkalaemia. Six patients had a total of seven episodes of
serum K+ >6.0 mEq/L, with the highest being 6.6 mEq/L in
one patient.
Mean serum magnesium levels were slightly lower (0.17
to 0.18 mg/dL) at all treatment visits (Week 4,Week 8, and
end-of-treatment visits) than at baseline; however, mean
levels remained within the normal range (1.8–2.4 mg/dL).
At Week 8, the mean [standard error (SE)] change from base-
line in serum magnesium was 0.18 (0.04) (range: 1.00 to
0.30). Eight (12.7%) patients had serum magnesium levels
<1.8 mg/dL [lower limit of normal (LLN)] during the treat-
ment period (with one having baseline level below the LLN);
of these, two (3.2%) patients had levels <1.4 mg/dL (none
<1.2 mg/dL). One patient with serum magnesium of
1.5 mg/dL reported moderate myalgia with onset on Day
29, which was resolved within a week after the patient re-
ceived a magnesium supplement. Mean serum magnesium
returned to near-baseline values 7 days post-treatment
(change from baseline, 0.03 mg/dL). No AEs of
hypomagnesaemia were reported.
There were no clinically relevant or statistically significant
changes in mean serum creatinine or eGFR values at Week
8. Mean (SE) change from baseline to Week 8 was +0.04
(0.04) mg/dL (range: 0.84 to 0.97) for serum creatinine
and 0.21 (1.11) mL/min/1.73 m2 (range: 16.0 to 18.0)
for eGFR. At baseline, 35 (55.6%) patients had micro-
albuminuria or macro-albuminuria [albumin-to-creatinine ra-
tio (ACR) ≥30 mg/g], with a mean (SD) ACR of 750
(1342) mg/g. The mean (SE) ACR decreased from baseline
to Week 8 by 291 (142) mg/g (range: 2536 to 1189;
n = 30; P <0.05).
Six patients were noted to have an eGFR of <30 mL/min/
1.73 m2 (range: 14–29 mL/min/1.73 m2) by central laboratory
results at baseline. All of these patients were successfully
uptitrated to spironolactone 50 mg/day (four at Week 1
and one at Week 2) and five were able to maintain this dose
of spironolactone throughout their participation in the study.
One patient was terminated early from the study because of
hyperkalaemia (serum K+ 6.0 and 5.6 mEq/L at Weeks 6 and
7, respectively) while on spironolactone 50 mg/day and
patiromer 8.4 g/day, and another patient was withdrawn
from the study at Day 25 because of an AE of diarrhoea. From
baseline to the end of treatment, there were no meaningful
changes in blood pressure, heart rate, ECG intervals or find-
ings, or physical examinations.
Discussion
Patiromer is a novel K+-binding polymer approved to treat
hyperkalaemia.10 Patiromer uses calcium, rather than so-
dium, as the counterion for K+ exchange.11 This avoids the po-
tential for increases in sodium absorption and retention in
patients with volume overload who may not tolerate even a
small increase in sodium load, such as those with hyperten-
sion, CKD, and/or HF.18,19 Patiromer has recently been shown
to reduce serum aldosterone levels in patients with CKD and
hyperkalaemia who are on RAASi.20 A previous trial, PEARL-HF,
demonstrated that, compared with placebo, a 25.2 g/day
fixed dose of patiromer prevented the development of
hyperkalaemia and was relatively well tolerated in patients
with HF receiving standard therapy and initiating
spironolactone (25–50 mg/day)16 but was associated with a
7% incidence of hypokalaemia (serum K+ <3.5 mEq/L).
The present study extends previous literature by
showing that patiromer initiated at a lower starting dose of
16.8 g/day followed by individual dose titration maintained
serum K+ within the target range in nearly all study patients.
The study population had characteristics that may make
spironolactone initiation clinically desirable but challenging:
HFrEF or HF with preserved EF (HFpEF) patients with CKD
and high rates of other cardiovascular risk factors, such as di-
abetes (43%) and hypertension (94%), all but one of whom
were on one or more RAASi at baseline. Spironolactone was
initiated at 25 mg/day, uptitrated to 50 mg/day to meet the
target doses used in HF trials1,4,5; in the present trial, all par-
ticipants achieved the 50 mg/day dose. At the end of the
treatment period, 90.5% of patients had serum K+ in the
range of 3.5–5.5 mEq/L, and 84.1% had serum K+ in the range
of 4.0–5.1 mEq/L.
Approximately one-third of the patients did not require
patiromer dose uptitration to maintain their serum K+ in
the range of 3.5–5.5 mEq/L. Among patients who did require
patiromer dose titrations, the majority needed only one or
two titrations to maintain their serum K+ levels within the tar-
get range, despite having CKD and receiving spironolactone
50 mg/day in addition to their standard therapy, including
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one or more RAASi. Patiromer’s efficacy in preventing
hyperkalaemia occurred against a background of diuretic
therapy in over 80% of patients; however, a previously pub-
lished analysis of OPAL-HK data showed a similar magnitude
and time course of reductions in serum K+ in CKD patients
with hyperkalaemia on and not on diuretics.21
Patiromer was generally well tolerated, with only mild to
moderate GI side effects in most patients and low rates of
discontinuation. Furthermore, the incidence of hypokalaemia
(1.6%) and serum magnesium below the LLN (12.7%) in the
present study was lower compared with the rates in PEARL-
HF (7% and 24%, respectively) that used a fixed higher dose
of patiromer, suggesting that patiromer initiated at a dose
of 16.8 g/day with subsequent individualized dose titrations
may be a more effective strategy for avoiding hypokalaemia
and serum magnesium <LLN than the 25.2 g/day fixed-dose
strategy used in PEARL-HF.16 There was a low incidence
(4.8%) of renal dysfunction, and in most patients, events of
hyperkalaemia were isolated, including in the six patients
with serum K+ measurements ≥6.0 mEq/L; none were above
6.6 mEq/L. There were no ECG abnormalities or serious car-
diovascular events associated with either hypokalaemia or
hyperkalaemia.
Select patients with HF and CKD have potential to derive
significant benefit from RAASi, especially MRAs,22 and MRAs
have a Class Ia recommendation from the ESC to reduce
the risk of HF hospitalization and death in HFrEF patients
who remain symptomatic on ACEi or beta-blocker therapy.6
In addition, spironolactone has also been shown to be effec-
tive in reducing atrial natriuretic peptide levels in HF patients
on an ACEi or an ARB and in overcoming diuretic resistance in
patients with HF.23,24 However, RAASi agents are frequently
not initiated or may be discontinued because of potential risk
for hyperkalaemia.25–27 A prospective analysis from BIOSTAT-
CHF showed that patients with HFrEF receiving less than 50%
of the recommended doses of ACEi, ARBs, and/or BBs
displayed more risk of death or hospitalization for HF com-
pared with those who receive ≥100%.28
In HFpEF or HF with mid-range EF (HFmrEF) patients, how-
ever, no RAASi has been shown to reduce morbidity and mor-
tality.6 Nonetheless, RAASi therapies, including MRAs, are
often used in clinical practice in HFpEF and HFmrEF patients
to manage coexisting conditions, such as hypertension, dia-
betes, and CKD and/or to provide symptom relief. In the large
European Society of Cardiology Heart Failure Registry, ap-
proximately 23% of ambulatory patients with chronic HF
had EF above 45%. Among these patients, 80% were pre-
scribed an ACEi or ARB, and 41% were prescribed an MRA.27
The present study enrolled patients with HF, 47% of whom
had EF >40%, and with CKD already receiving background
therapy of an ACEi, ARB, and/or a BB and challenged them
with a dosing regimen of spironolactone. The role of
spironolactone in HFpEF patients remains uncertain,29–31 al-
though MRAs received a Class IIb recommendation in the
recently updated American Heart Association/American Col-
lege of Cardiology HF guidelines to reduce hospitalization in
appropriately selected patients with HFpEF.4 Nonetheless,
the results of this study suggest that, in HF patients who, in
the opinion of their treating physician, may benefit from
spironolactone initiation and uptitration to 50 mg, patiromer
was able to maintain serum K+ in the target range in the ma-
jority of patients; this was achieved with improved control of
hyperkalaemia and a low incidence of hypokalaemia and
hypomagnesaemia, as well as acceptable tolerability. The
ability to manage or prevent hyperkalaemia may remove
one obstacle to the use of MRAs in HF patients who have
an indication for such therapy.
Limitations
The most important limitation in the present study is the lack
of a control group. However, there was a control group in the
PEARL-HF study,16 which demonstrated a significant reduc-
tion in the incidence of hyperkalaemia in patients on
patiromer vs. placebo who were initiated on spironolactone
25 mg/day with subsequent uptitration to 50 mg/day.
In addition to the inclusion of patients with HFpEF and
HFmrEF, several patients in the present study who received
spironolactone in an attempt to test the effectiveness of
patiromer in preventing hyperkalaemia did not conform to
current guidelines for the use of an MRA due to an
eGFR <30 mL/min/1.73 m2. The inclusion of only six patients
with an eGFR <30 mL/min/1.73 m2 in the present
study was likely related to the current guidelines, which
recommend initiating spironolactone in HF patients with
eGFR >30 mL/min/1.73 m2.4,6 Nonetheless, results of this
study provide useful information for the development of fu-
ture trials to evaluate patiromer in a broad group of patients
who might be at risk for the development of hyperkalaemia if
administered an ACEi or ARB and an MRA. Many of these pa-
tients, while at significantly increased risk for cardiovascular
death and hospitalization for HF, are currently not treated
with an MRA due to the fear of inducing hyperkalaemia.
Conclusions
Patiromer initiated at a dose of 16.8 g/day with subsequent
individualized dose titrations (needed by two-thirds of pa-
tients) maintained serum K+ within the target range in the
majority of patients with HF and CKD in the present open-
label study, all of whom were uptitrated to spironolactone
50 mg/day, with a relatively low incidence of hyperkalaemia.
This strategy was accomplished with a low incidence of
hypokalaemia, hypomagnesaemia, and renal dysfunction.
With a dose-titration strategy, patiromer appears to be effec-
tive and safe, and our findings should allow development of
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further prospective, randomized controlled trials to evaluate
this strategy in high-risk patients such as those with HFrEF
and eGFR <30 mL/min/1.73 m2.
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